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parison to non-PEG. The incremental cost per QALY
gained is €4289. The weighted average incremental 
cost-effectiveness ratio, using population-based HCV
genotype distribution estimates, for all genotypes was
€9473 per QALY. CONCLUSION: Peginterferon alfa-2a
(40KD)/ribavirin is a cost-effective therapy for treatment
of naive adults with CHC compared with standard inter-
feron alfa-2b/ribavirin, regardless of HCV genotype.
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OBJECTIVES: Due to the high prevalence of hepatitis B
infection in some Asian countries and the associated 
morbidity and mortality, widespread treatment of chronic
hepatitis B treatment would have major public health
implications in these countries. We evaluated the cost-
effectiveness of 3 treatment regimens for chronic hepati-
tis B (interferon-alpha for 16 weeks, lamivudine for 
1 year, and lamivudine for 3 years) vs. no treatment 
in Taiwan, where government-sponsored universal 
health insurance have been implemented since 1995.
METHODS: We followed international guidelines on
cost-effectiveness analysis and constructed a Markov
model to project disease progression and health care
expenditure among hypothetical cohorts of 30-year-old
chronic hepatitis B patients. We adopted the societal 
perspective and a 70-year time frame since treatment 
initiation. Taiwan-speciﬁc disease, quality-of-life, and
costs information was used for virtually all model para-
meters. Outcome of interest was the Incremental Cost-
Effectiveness Ratio (ICER) in Taiwan Dollar (TWD,
US$1 = 34.41TWD on January 13, 2003) per QALY.
RESULTS: For a 30-year-old chronic hepatitis B patient
under base-case assumption, projected increase in life
expectancy was 1.84 years, 2.01 years, and 3.9 years if
s/he was treated with interferon, lamivudine for one year,
and lamivudine for three years, respectively. ICERs
(TWD/QALY) with 3% annual discount rate were 34,700
for interferon, 17,400 for 1 year of lamivudine, and
46,200 for 3 years of lamivudine. Monte Carlo simula-
tion showed robust results with respect to a wide range
of parameter assumptions and each of the three treatment
regimens could result in costs-savings. In multi-way sen-
sitivity analysis, the upper range of 95% of the ICERs
(with 3% annual discount rate) were 204,100 for inter-
feron, 127,800 for 1 year of lamivudine, and 197,900 for
3 years of lamivudine. CONCLUSIONS: Using lamivu-
dine to treat of chronic hepatitis B among young adults
in Taiwan would result in substantial gain in life
expectancy.
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OBJECTIVES: Approximately 350 million patients have
Chronic HBV infection worldwide. In Brazil there are
more than 3 million chronically infected with HBV. HBV
infection leads to chronic liver disease states such as cir-
rhosis, hepatocarcinoma and the need for transplanta-
tion. There is little published data on the cost of HBV in
Brazil. The aim of this study is to investigate treatments
patterns, medical resource use and treatment costs for
each state of HBV infection. METHODS: A question-
naire was developed and a physician survey conducted to
obtain information about the treatment patterns for
Chronic HBV in Brazil. Data were collected from physi-
cians in seven hospitals, across three different regions of
Brazil. Cost information was derived predominantly from
the government pay schedule; private hospital services
and pharmacy cost tables for medical care in Brazil.
RESULTS: Patients were separated into those managed
with and without antiviral medications. Lamivudine 
and Interferon alfa 2-B were the most common used
antiviral agents, with a cost of R$921.17 (year patient)
and R$15,424 (year/patient) respectively. The expected
annual costs per patient were: R$7,561 (R$1,030,
R$17,374) for chronic hepatitis B with antiviral medica-
tion, R$326 (R$212, R$512) for chronic hepatitis B
without antiviral medication, R$6,279 (R$1,030,
R$17,377) for compensated cirrhosis with antiviral 
medication, R$384 (R$212, R$555) for compensated 
cirrhosis without antiviral medication, R$16,522
(R$3,392, R$44,336) for decompensated cirrhosis,
R$39,895 (R$38,678, R$41,112) for liver transplanta-
tion, R$29,858 (R$26,513, R$33,202) for transplant
care after the ﬁrst year and R$2,382 (R$1,731, R$3,032)
for hepatocellular carcinoma. CONCLUSIONS: These
cost data can be used to model disease burden in Brazil.
Cost of antiviral medications inﬂuence disease costs in
chronic HBV and compensated cirrhosis states. Costs
increase dramatically in the more advanced health states,
and indicate that slowing progression to these states may
be cost savings. One USD = 3 R$ at the moment of the
survey.
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